Early prophylactic low-dose hydrocortisone for bronchopulmonary dysplasia prevention in extremely preterm infants: a systematic review and meta-analysis
8 affiliations
- 1College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
- 2College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- 3College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Jeddah, Saudi Arabia
- 4Saudi Board in Pediatric, Riyadh, Saudi Arabia
- 5College of Medicine, Almaarefa University, Riyadh, Saudi Arabia
- 6Department of Pediatric, Prince Mohammed Bin Abdulaziz Hospital, Madinah, Saudi Arabia
- 7King Saud Medical City, Riyadh, Saudi Arabia
- 8Department of Pediatrics Hematology and Oncology, King Saud Medical City, Riyadh, Saudi Arabia
Abstract
BackgroundEarly prophylactic low-dose hydrocortisone has been proposed to reduce inflammation and to compensate for relative adrenal insufficiency in extremely preterm infants. Its overall balance of benefit and risk remains uncertain.ObjectiveTo evaluate whether hydrocortisone initiated within the first 24–48 h after birth reduces bronchopulmonary dysplasia (BPD) and mortality in infants born before 30 weeks' gestation.MethodsThis systematic review and meta-analysis followed PRISMA 2020 guidance and was registered in PROSPERO. PubMed, Cochrane CENTRAL, Scopus, and Web of Science were searched from inception to May 2026. Eligible studies enrolled infants born before 30 weeks' gestation who received early prophylactic systemic hydrocortisone at a low dose. Low dose was defined as a starting dose of no more than 2.0 mg/kg/day, begun within 24–48 h of birth. The comparator was placebo or no hydrocortisone. Randomized and quasi-randomized trials, their follow-up reports, and comparative observational studies were eligible. Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs).ResultsFourteen studies with 3,416 infants were included. Early hydrocortisone did not significantly improve survival without BPD at 36 weeks' postmenstrual age (RR: 1.07, 95% CI: 0.97–1.19, p = 0.18). It also did not significantly reduce BPD at 36 weeks (RR: 0.94, 95% CI: 0.85–1.04, p = 0.25) or mortality before discharge (RR: 1.07, 95% CI: 0.77–1.49, p = 0.69). The duration of respiratory support and the need for oxygen at discharge were similar between groups. Subgroup analyses suggested a possible benefit in infants exposed to chorioamnionitis and in those born before 26 weeks, but these findings were exploratory. Hydrocortisone increased the risk of late-onset sepsis (RR: 1.19, 95% CI: 1.05–1.35, p = 0.01). Gastrointestinal perforation, necrotizing enterocolitis, major neonatal morbidities, and the available neurodevelopmental outcomes did not differ significantly between groups.ConclusionCurrent evidence does not support the routine use of early prophylactic hydrocortisone in all extremely preterm infants. Adequately powered trials and individual patient data analyses are needed to identify the subgroups most likely to benefit and to clarify long-term safety.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/view/CRD420261402317, PROSPERO CRD420261402317.
Related
- Diuretics for Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension in Preterm Infants-A Systematic Review.
- Bovine milk-derived osteopontin attenuates hyperoxia-induced lung injury associated with NLRP3 inflammasome regulation in neonatal mice with bronchopulmonary dysplasia
- Toward Endotype-Based Bronchopulmonary Dysplasia: Evolving Definitions and the Role of Translational Models
- Renal outcome at 2 years in neonates with nephrocalcinosis and bronchopulmonary dysplasia: a case-control study.
- Transcatheter atrial septal defect closure in infants weighing 3 to 6 kg with clinically significant bronchopulmonary dysplasia
BibTeX
@article{shehadeh2026early,
title = {{Early prophylactic low-dose hydrocortisone for bronchopulmonary dysplasia prevention in extremely preterm infants: a systematic review and meta-analysis}},
author = {Lamar Abu Shehadeh and Tala Adel Al Ghamdi and Rahaf Atiah Alzahrani and Bayan Yahya Mushari and Layan Abdulrahman Alotaibi and Lara Sadik and Omar Mohammad Kheder and Turki Hagr and Bedah Mohammed Alnawfal},
journal = {Frontiers in Pediatrics},
year = {2026},
month = oct,
doi = {10.3389/fped.2026.1934115},
url = {https://doi.org/10.3389/fped.2026.1934115},
note = {CC BY},
}
RIS
TY - JOUR
TI - Early prophylactic low-dose hydrocortisone for bronchopulmonary dysplasia prevention in extremely preterm infants: a systematic review and meta-analysis
AU - Lamar Abu Shehadeh
AU - Tala Adel Al Ghamdi
AU - Rahaf Atiah Alzahrani
AU - Bayan Yahya Mushari
AU - Layan Abdulrahman Alotaibi
AU - Lara Sadik
AU - Omar Mohammad Kheder
AU - Turki Hagr
AU - Bedah Mohammed Alnawfal
PY - 2026
DA - 2026/10/26
JO - Frontiers in Pediatrics
DO - 10.3389/fped.2026.1934115
UR - https://doi.org/10.3389/fped.2026.1934115
AB - BackgroundEarly prophylactic low-dose hydrocortisone has been proposed to reduce inflammation and to compensate for relative adrenal insufficiency in extremely preterm infants. Its overall balance of benefit and risk remains uncertain.ObjectiveTo evaluate whether hydrocortisone initiated within the first 24–48 h after birth reduces bronchopulmonary dysplasia (BPD) and mortality in infants born before 30 weeks' gestation.MethodsThis systematic review and meta-analysis followed PRISMA 2020 guidance and was registered in PROSPERO. PubMed, Cochrane CENTRAL, Scopus, and Web of Science were searched from inception to May 2026. Eligible studies enrolled infants born before 30 weeks' gestation who received early prophylactic systemic hydrocortisone at a low dose. Low dose was defined as a starting dose of no more than 2.0 mg/kg/day, begun within 24–48 h of birth. The comparator was placebo or no hydrocortisone. Randomized and quasi-randomized trials, their follow-up reports, and comparative observational studies were eligible. Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs).ResultsFourteen studies with 3,416 infants were included. Early hydrocortisone did not significantly improve survival without BPD at 36 weeks' postmenstrual age (RR: 1.07, 95% CI: 0.97–1.19, p = 0.18). It also did not significantly reduce BPD at 36 weeks (RR: 0.94, 95% CI: 0.85–1.04, p = 0.25) or mortality before discharge (RR: 1.07, 95% CI: 0.77–1.49, p = 0.69). The duration of respiratory support and the need for oxygen at discharge were similar between groups. Subgroup analyses suggested a possible benefit in infants exposed to chorioamnionitis and in those born before 26 weeks, but these findings were exploratory. Hydrocortisone increased the risk of late-onset sepsis (RR: 1.19, 95% CI: 1.05–1.35, p = 0.01). Gastrointestinal perforation, necrotizing enterocolitis, major neonatal morbidities, and the available neurodevelopmental outcomes did not differ significantly between groups.ConclusionCurrent evidence does not support the routine use of early prophylactic hydrocortisone in all extremely preterm infants. Adequately powered trials and individual patient data analyses are needed to identify the subgroups most likely to benefit and to clarify long-term safety.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/view/CRD420261402317, PROSPERO CRD420261402317.
SN - 2296-2360
ER -